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arterial hypertension on stable treatment with oral pulmo-
nary arterial hypertension-approved drugs (90% on dual 
combination therapy) were included. Patients achieved a 
median treprostinil dosage of 35.7 ng/kg/min after 16 weeks. 
A good overall safety profile was demonstrated with 3 pa-
tients (8%) withdrawing due to infusion site pain, which oc-
curred in 97% of patients. After 16 weeks, median 6-min 
walking distance, cardiac index, pulmonary vascular resis-
tance, and tricuspid annular plane systolic excursion im-
proved.  Conclusions: Rapid up-titration of subcutaneous 
treprostinil was well tolerated, achieving a clinically effective 
dose associated with improvement of exercise capacity and 
haemodynamics after 16 weeks. A rapid dose titration regi-
men and proactive infusion site pain management may im-
prove the handling of this therapy and contribute to better 
treatment outcome.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: Subcutaneous treprostinil has dose-depen-
dent beneficial effects in patients with severe pulmonary ar-
terial hypertension, but adverse effects like infusion site pain 
can lead to treatment discontinuation.  Objectives: The ob-
jective of this study was to evaluate safety, tolerability and 
clinical effects of a rapid up-titration dosing regimen of sub-
cutaneous treprostinil using proactive infusion site pain 
management.  Methods: Effects of rapid up-titration dosing 
regimen on tolerability and clinical parameters were evalu-
ated in this 16-week, open-label multi-centre study.  Results: 
Thirty-nine patients with idiopathic or heritable pulmonary 
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 Introduction 
 Pulmonary arterial hypertension (PAH) is a rare, life-
threatening condition that is characterised by a progres-
sive increase in pulmonary vascular resistance (PVR), re-
sulting in chronic right heart failure and premature death. 
The loss of endogenous prostacyclin plays an important 
role in the pathogenesis of PAH. Prostacyclin has vaso-
dilatory, anti-proliferative, anti-inflammatory and anti-
thrombotic properties and is therefore an important tar-
get substance in PAH-specific therapy  [1] . Epoprostenol 
was the first specific therapy approved for the treatment 
of PAH, after showing a positive effect on survival  [2] . 
Epoprostenol is chemically unstable with a short biologi-
cal half-life of 3–5 min, and must be continuously admin-
istered by intravenous (IV) infusion using an external 
pump and indwelling central venous catheter.
 Treprostinil, which can be administered by either sub-
cutaneous (SC) or IV infusion, has improved stability with 
a terminal elimination half-life of  ∼ 4 h  [3] . A permanent 
central venous catheter can be avoided by using SC ther-
apy. The medication is continuously administered via a 
micro-infusion pump using a small-bore catheter and SC 
cannula which can be self-inserted by the patient. Treat-
ment with SC treprostinil has been shown to improve ex-
ercise capacity, symptoms and haemodynamics in pa-
tients with PAH in a dose-dependent manner  [4] , and 
may improve long-term outcome  [5–7] . Local adverse re-
actions, including infusion site pain, mild bleeding and 
swelling, can lead to discontinuation of treatment  [5, 6] 
and may cause a slow and reluctant dose titration, pro-
longing the time until treatment is clinically effective. 
There is, however, no apparent correlation between local 
adverse reactions and treprostinil dose rate  [3, 8] . By con-
trast, rapid dose escalation has been reported to cause less 
frequent site pain (58 vs. 82%, p = 0.04) and a significant-
ly greater improvement of 6-min walk distance (6MWD; 
p = 0.03) compared with slow dose escalation  [3] . Trepro-
stinil dose rate has also been found to be an independent 
prognostic on-treatment predictor of survival in a retro-
spective analysis of 811 patients treated with SC treprosti-
nil  [9] . A slow dose titration is therefore a potential cause 
of sub-therapeutic dosages  [10] , which may provoke pre-
mature discontinuation of treatment. A thorough medical 
management of SC treprostinil therapy, including multi-
disciplinary patient support and proactive infusion site 
pain management, is necessary to achieve a clinically ef-
fective dosing regimen  [10] . Importantly, infusion site 
pain can be minimised by avoidance of infusion site re-
placement until clinically indicated. A rapid treatment 
initiation of epoprostenol has already been shown to sig-
nificantly improve haemodynamics and clinical outcome 
compared to a slow titration regimen  [11, 12] .
 Up to now, a rapid dosing regimen of treprostinil has 
only been investigated in a small group of 12 patients  [3] . 
It is not clear whether this regimen, together with a pro-
active approach to infusion site pain management, can be 
well tolerated and effective in a larger patient cohort. 
Therefore, the aim of this study was to investigate pro-
spectively the safety and tolerability of a rapid dose titra-
tion regimen together with proactive infusion site man-
agement of SC treprostinil in a larger cohort of patients 
with severe PAH. Furthermore, the clinical effects after a 
treatment period of 16 weeks were to be evaluated.
 Materials and Methods 
 Study Design 
 This was an open-label, single-territory, multi-centre study de-
signed to evaluate the safety, tolerability and clinical effects of a 
rapid dose titration regimen of SC treprostinil in subjects with se-
vere PAH.
 Patients/Setting 
 Subjects were either treatment naïve or receiving an approved 
endothelin receptor antagonist (ERA) and/or an approved phos-
phodiesterase (PDE)-5 inhibitor for at least 60 days and main-
tained on a stable dose for at least 30 days prior to providing in-
formed consent. Thirty-nine patients were enrolled across 10 cen-
tres throughout Germany from 16 April 2012 to 20 March 2014 to 
ensure a minimum of 30 completing patients  [6] . Thirty complet-
ing patients were believed to be the minimum requirement to show 
tolerance to the rapid titration regimen. The main entry criteria for 
the study are summarised in  table 1 .
 Enrolment and Treprostinil Treatment 
 SC treprostinil was initiated on an in-patient basis (minimum 
of 72 h) and under medical supervision at approximately 2 ng/kg/
min with dose increments of 1–2 ng/kg/min approximately every 
12 h according to tolerability. The length of hospital stay was deter-
mined by subject competency to administer SC treprostinil using a 
micro-infusion pump (Crono 5; Canè Medical Technology), cou-
pled with either the Cleo (Smiths Medical) or Quickset (Medtronic) 
infusion set. The SC infusion cannula remained in situ for as long 
as clinically appropriate because infusion site pain has been shown 
to diminish over  ∼ 5 days following the insertion of each new can-
nula  [7] . To avoid regular insertion site changes, site pain was man-
aged by proactive application of topical and systemic analgesics, 
and patients were taught how to maintain a sterile site.
 Following discharge from hospital, dose increases of 1–2 ng/kg/
min were permitted every 24 h. Once a dose rate of 20 ng/kg/min 
had been achieved, the dose increments could be up to 4 ng/kg/min 
separated by at least 24 h based on tolerability. The aim was to 
achieve a target dose of 10, 20 and 30 ng/kg/min by the end of weeks 
1, 4 and 12, respectively, and a dose rate by the end of 16 weeks that 
achieved and maintained the pre-defined treatment goals, as follows:
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 Table 1.  Main inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1 Minimum 18 years of age and written informed consent 1 Pregnant or lactating
2 Weight at least 40 kg and body mass index less than 40 2 Received epoprostenol, treprostinil, IV iloprost, or 
beraprost within 30 days prior to screeninga
3 Using two effective forms of contraception required for females, 
and males to use a condom throughout the study and for 64 days 
following treatment cessation 
3 Previous intolerance or significant lack of efficacy to 
treatment with prostacyclin or prostacyclin analogues
4 Diagnosed with symptomatic idiopathic or heritable PAH 4 Any disease associated with pulmonary hypertension or 
an atrial septostomy
5 6MWD at least 150 and no more than 550 m 5 WHO-FC IV
6 Treatment naïve or receiving an approved PDE-5 inhibitor and/
or an approved ERA for at least 60 days and on a stable dose for 
at least 30 days prior to screening
6 Uncontrolled sleep apnoea
7 Optimally treated with conventional pulmonary hypertension 
therapy with no changes for at least 14 days prior to screening
7 AST and ALT more than 3 times the upper limit of the 
laboratory reference range and/or an international 
normalised ratio more than 3 units at screening
8 Right heart catheterisation conducted within 8 weeks prior to or 
during the screening period with:
8 Clinically significant bleeding episode within the previous 
6 months, or any other condition that would either 
jeopardise subject safety and/or interfere with 
interpretation of assessments
a
b
c
Mean pulmonary artery pressure at least 25 mm Hg
Pulmonary capillary wedge pressure (PCWP) no more than 
15 mm Hg
PVR more than 3 Wood unitsb
9 Echocardiography with evidence of clinically normal left 
ventricular function, absence of left-sided heart disease and 
unrepaired congenital heart disease
9 History of ischaemic heart disease within the previous 6 
months of screening, or history of left-sided myocardial 
disease as evidenced by a PCWP greater than 15 mm Hg 
or left ventricular ejection fraction less than 40%
10 Ventilation perfusion lung scan, high-resolution computerised 
tomography scan of the chest and/or pulmonary angiography 
consistent with the diagnosis of PAH 
10 Uncontrolled systemic hypertension as evidenced by:
a
b
Systolic blood pressure above 160 mm Hg
Diastolic blood pressure above 100 mm Hg
11 Pulmonary function tests conducted within previous 9 months 
demonstrating:
11 Musculoskeletal disorder or other disease that would limit 
ambulation or was connected to a machine that was not 
portablea
b
Total lung capacity at least 60%
FEV1/FVC ratio at least 50%
12 Unstable psychiatric condition or any condition which 
would constitute an unacceptable risk to subject safety
13 Any investigational drug, investigational device in place 
or participation in an investigational study 30 days prior 
to screening
 Entry criteria taken from the latest protocol version. a Subjects who had administered inhaled prostacyclins prior to entry were now 
permitted provided usage ceased prior to enrolment. Due to the short wash-out period of these agents, their use prior to study enrolment 
was believed to have no impact on efficacy outcomes of the study. b Study-defined timelines for pre-screening right heart catheter was 
extended from 4 to 8 weeks. Little or no change in parameters was expected over this extended period, and this timeline was believed to 
be more ethical for study subjects.
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 1 World Health Organisation (WHO) functional class (FC) II
 2 6MWD greater than 400 m (or increase of more than 30 m if 
baseline 6MWD was greater than 400 m or if 400 m could not 
be reached)
 3 Tricuspid annular plane systolic excursion (TAPSE) as mea-
sured by echocardiography greater than 2 cm. Patients achiev-
ing one or more goals were considered to be treatment re-
sponders.
 Outcome Measures and Safety 
 The primary objective to evaluate safety and tolerability was 
assessed throughout the study by monitoring adverse events (AEs), 
vital signs, severity of PAH symptoms (including fatigue, dys-
pnoea, oedema, dizziness, syncope, chest pain and orthopnoea) 
and physical examination. Overall tolerability of the rapid up-ti-
tration regimen was quantified by assessing the number of subjects 
who remained on treprostinil therapy for 16 weeks without expe-
riencing a treprostinil-related serious AE (SAE).
 The secondary efficacy endpoints included the changes from 
baseline to week 16 in exercise capacity (assessed using the 6MWD 
 [13] and the Borg dyspnoea score), N-terminal pro-brain natri-
uretic peptide (NT pro-BNP) plasma concentration, WHO-FC, 
TAPSE and tricuspid regurgitant jet velocity (TRJV) (assessed by 
echocardiography), symptoms of PAH, and cardiopulmonary hae-
modynamics measured by right heart catheterisation (RHC). Sub-
ject quality of life was assessed using the Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR) questionnaire.
 Statistical Analysis 
 The study population was defined as all subjects enrolled into 
the study. In general, the data were summarised by scheduled as-
sessment. For continuous variables, the summary statistics includ-
ed the mean, standard deviation, standard error, median, lower 
and upper quartile, and minimum and maximum values. For the 
purposes of describing the difference between baseline and follow-
up assessments, p values from Wilcoxon signed-rank test (for con-
tinuous variables) were included, but were not intended to test 
formal hypotheses. All values that were missing or deemed un-
known were omitted from any analysis. No pre-defined co-variates 
were used in the analysis of the data.
 Ethical Standards 
 The study was conducted in compliance with Good Clinical 
Practice guidelines and in accordance with the principles defined 
in the amended Declaration of Helsinki. The protocol was ap-
proved by the German regulatory authority (BfArM) and the cen-
tral and local ethics committees of the Universities of Heidelberg, 
Cologne, Dresden, Regensburg, Leipzig, Munich and Saarbruck-
en, and of the medical council Hamburg, Munich and Dusseldorf. 
Written informed consent was obtained from all subjects prior to 
the conduct of any study-specific activities.
 Results 
 Baseline Characteristics and Patient Disposition 
 Patient disposition and baseline demographics are 
summarised in  figure 1 and  table 2 , respectively. A total 
of 40 subjects were screened for the study. Thirty-nine 
32 completed
39 enrolled
40 screened
• 3 adverse events
• 2 withdrew consent
• 1 clinical deterioration
• 1 implantable pump
7 discontinued
 Fig. 1. Flowchart of study patients. 
 Table 2. Summary of demographic and other baseline characteristics
Baseline parameter Baseline value/
number (n = 39)
Age, years
Mean (median)
Range
52.7 (50)
25 – 82
Gender, n (%)
Female
Male
29 (74.4)
10 (25.6)
PAH aetiology, n (%)
Idiopathic/heritable 39 (100)
Background oral PAH therapy, n (%)
None
ERA only
PDE-5 inhibitor only
ERA and PDE-5 inhibitor
1 (2.6)
1 (2.6)
2 (5.1)
35 (89.7)
Baseline 6MWD, m
Mean ± SD
Range
Median (Q1, Q3)
355 ± 93.1
163.0 – 547.0
352 (288.0, 423.0)
Borg dyspnoea score (1 – 10)
Mean ± SD
Median (Q1, Q3)
4.5 ± 1.9
5.0 (3.0, 6.0)
WHO-FC, n (%)
II
III
6 (15.4)
33 (84.6)
6MWD = Six-min walk distance; ERA = endothelin receptor 
antagonist; PAH = pulmonary arterial hypertension; PDE-5 = 
phosphodiesterase-5; SD = standard deviation; WHO = World 
Health Organization; Q1 = first quartile; Q3 = third quartile.
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subjects fulfilled the entry criteria and were enrolled and 
commenced on SC treprostinil therapy. Seven subjects 
(18%) prematurely terminated the study before comple-
tion of the 16-week treatment period: 3 withdrew due to 
treatment-related AEs (infusion site pain, diarrhoea and 
nausea), 2 withdrew consent, 1 discontinued due to clin-
ical deterioration, and 1 subject transitioned to IV trepro-
stinil and was withdrawn from the study.
 The proportion of female subjects (74%) was almost 
three times that of the males (26%) enrolled. Thirty-five 
subjects (90%) were on dual oral background therapy 
(PDE-5 inhibitor and ERA), 3 subjects were on mono-
therapy (2 subjects on a PDE-5 inhibitor, 1 on an ERA) 
and 1 subject was treatment naïve. The median baseline 
6MWD was 352 m with a median Borg dyspnoea score of 
5.0. The majority of subjects (33/39; 85%) were in WHO-
FC III, with the remainder (6/39; 15%) in WHO-FC II.
 Primary Objective: Safety and Tolerability 
 AEs experienced by at least 20% of the patients are out-
lined in  table 3 . A total of 374 AEs were recorded. All sub-
jects experienced at least one event during the study. The 
most frequently recorded AE reported by 38/39 subjects 
(97%) was infusion site pain. Infusion site pain was rea-
sonably well tolerated, and was associated with study 
drug discontinuation in only 3 (8%) subjects. In general, 
AEs were well tolerated, with symptomatic treatments 
prescribed at the discretion of the investigators. Opioids 
were prescribed 35 times in the form of oral treatment, 
including morphine on five occasions. Mainly hydro-
morphone and oxycodone were used. Most of the pa-
tients received non-steroidal analgesics (e.g., ibuprofen, 
paracetamol, diclofenac). There were 27 SAEs reported 
by 11/39 subjects (28%). Thirteen SAEs, which occurred 
in 7/39 subjects (18%), were considered to be related to 
treprostinil. Three of those related SAEs, diarrhoea, nau-
sea and infusion site pain, occurred in more than 1 sub-
ject.
 Secondary Objective: Efficacy 
 Exercise Capacity 
 Table 4 provides a summary of the median 6MWD to-
gether with the median dose of treprostinil achieved by 
all patients remaining on therapy at each time point. The 
effects seen during the treatment period are illustrated in 
 figure 2 . The results of the Wilcoxon signed-rank test in-
dicate that the week 12 and week 16 6MWD ranks were 
statistically significantly higher than the baseline 6MWD 
ranks (p = 0.0409 and p = 0.0086, respectively). Median 
changes from baseline of 14.0 and 11.5 m were observed 
at weeks 12 and 16, respectively. This indicates that there 
was an improvement in exercise capacity for the 32 sub-
jects (82%) who were able to tolerate the rapid up-titra-
tion of SC treprostinil therapy to 30 ng/kg/min and com-
pleted the 16-week treatment period. The targeted dosage 
of at least 30 ng/kg/min was achieved by 25 (78%) of the 
32 patients who completed the 16-week treatment period 
of the study.
 Other Clinical Parameters 
 There were beneficial and statistically significant 
changes in other important clinical parameters assessed 
during the 16-week treatment period ( table 5 ). A median 
change from baseline in plasma NT pro-BNP of –182 pg/
 Table 3. AEs experienced by at least 20% of patients
Preferred term Subjects, n (%)
(n = 39)
Events, n
Any adverse event 39 (100) 374
Infusion site pain 38 (97.4) 39
Diarrhoea 30 (76.9) 30
Headache 27 (69.2) 29
Nausea 20 (51.3) 20
Vomiting 15 (38.5) 16
Infusion site erythema 10 (25.6) 10
Dyspnoea 9 (23.1) 9
Pain in jaw 9 (23.1) 9
Dizziness 8 (20.5) 8
Vertigo 8 (20.5) 8
Visit
0
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kg
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Week 4
n = 36
Week 8
n = 33
Week 12
n = 30
Week 16
n = 30
n = 39
n = 34
n = 34
n = 32
Median change in 6MWD
Median treprostinil dose (ng/kg/min)
 Fig. 2. Change of median 6MWD and treprostinil dosage through-
out the study. 
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ml, and an improvement in WHO-FC at week 16 com-
pared to baseline in 25% of subjects was observed. Only 2 
patients (6.3%) worsened, one from WHO-FC II to III, 
and the other from WHO-FC III to IV. Median changes 
from baseline in the cardiac index of 0.3 l/min/m 2 (p < 
0.0001) and PAPm of –4.0 mm Hg were associated with 
a median change from baseline in PVR index of –2.7 mm 
Hg/min/m 2 /l (p < 0.0001), suggesting an overall improve-
ment in cardiopulmonary haemodynamics. This was fur-
ther supported by median changes from baseline to week 
16 of 0.1 cm and –0.3 m/sec in the TAPSE and TRJV, re-
spectively, which are consistent with an improvement in 
right ventricular performance. After 16 weeks, there was 
a significant improvement in patient outcome assessed by 
the CAMPHOR questionnaire (p = 0.0040), which could 
also be seen in a significant improvement of the two sub-
scales, Symptoms (p = 0.0105) and Activity (p = 0.0094). 
The CAMPHOR subscale score ‘quality of life’ also im-
proved, although this was not statistically significant (p = 
0.0845). There was no clear change in the severity of PAH 
symptoms recorded during the study. However, the over-
all effects observed during the study indicate that a rapid 
up-titration dosing regimen for SC treprostinil therapy 
administered to subjects with severe PAH can improve 
exercise capacity, functional performance and cardiopul-
monary haemodynamics.
 Treatment Goals 
 Analysis of the pre-defined, protocol-specified treat-
ment goals achieved by those patients who remained on 
treprostinil therapy for the 16-week treatment period of 
the study is summarised in  table 6 . The number of pa-
tients who achieved each of the individual criteria is 
shown together with the number of patients that met 
multiple goals. In line with the criteria for defining a treat-
ment responder, a total of 20/39 (51%) of the enrolled 
subjects achieved at least one pre-defined treatment goal 
on SC treprostinil therapy when administered in accor-
dance with the rapid up-titration dosing regimen. In 18 
of the 20 aforementioned patients, achievement of treat-
ment goals was due to improvement of clinical parame-
ters during the study: the remaining 2 subjects remained 
WHO-FC II from baseline through to week 16.
 Discussion 
 To the best of our knowledge, this is the first prospec-
tive multicentre study investigating the effect of rapid 
dose titration of SC treprostinil, together with a proactive 
approach to infusion site management and RHC per-
formed at baseline and after 16 weeks. Rapid dose titra-
tion was generally well tolerated and led to a clinically 
effective dosage, as demonstrated by an improvement in 
exercise capacity and haemodynamics during the 16-
week study period. A rapid dose titration and proactive 
infusion site management may therefore improve the 
management of this therapy and contribute to an im-
proved treatment outcome.
 Clinically effective dosages could be reached by rapid 
dose titration and were generally tolerable. Compared to 
the rapid dose titration scheme used by Skoro-Sajer et al. 
 [3] , the mean dosages achieved after 4, 8 and 12 weeks 
were considerably higher in this study, with 32.0 com-
Visit Week 4
(n = 36)
Week 8
(n = 33)
Week 12
(n = 30)
Week 16
(n = 30)
Median baseline 6MWD, m 353 352 348 351
Q1
Q3
291
427
294
420
288
423
294
420
Median visit 6MWD, m 395 360 402 419
Q1
Q3
297
460
300
453
320
462
309
468
Median change in 6MWD from baseline, m 10 9 14 11.5
p value 0.0113 0.2368 0.0409 0.0086
Treprostinil dose rate, ng/kg/min
Median 
Q1
Q3
Patients, na
17.2
14.5
22.4
39
26.8
22.5
30.7
34
32.6
27.0
36.2
34
35.7
31.1
41.0
32
6MWD = Six-min walk distance; Q1 = first quartile; Q3 = third quartile. a Number of patients 
completing the given assessment at the visit outlined.
 Table 4. Summary of 6MWD and 
treprostinil dose rate achieved during the 
study
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pared to 20.3 ng/kg/min after 12 weeks. AEs, especially 
infusion site pain, did not differ substantially from previ-
ous studies, even though higher dosages were achieved 
within the 16-week study period.
 Infusion site pain occurred in 97% of the patients, 
which is comparable to the rate reported by Barst et al. 
 [6] , but higher than the rate of 82% that was detected by 
Lang et al.  [5] and by Skoro-Sajer et al.  [3] . In our patient 
cohort, the finding of a significantly lower incidence 
(58%) of infusion site pain when using a rapid dose titra-
tion regimen  [3] was not confirmed. The study by Skoro-
Sajer et al.  [3] only included 12 patients performing rapid 
dose titration, which may have limited the reliability of 
the results. In addition, only site pain experienced by pa-
tients from Vienna was systematically assessed by a vi-
sual analogue scale, which may have led to less frequent 
reporting of site pain compared to a systematic assess-
ment in all of our study patients. Furthermore, in up to 
20% of patients investigated by Skoro-Sajer et al.  [3] , infu-
sion site pain required drug interruption. In our patient 
cohort, only 8% of patients discontinued treatment due 
to infusion site pain, which is comparable to the frequen-
cy of discontinuation due to site pain reported by Barst et 
al.  [6] . In that study, out of a cohort of 860 patients, 196 
discontinued treatment due to infusion site pain (23%) 
during a mean duration of exposure of 2.6 ± 0.8 years. 
Within the first 6 months, 50% of the patients who dis-
continued due to site pain had already stopped treatment 
and had a comparable dropout rate to our cohort after 16 
weeks of treatment  [6] . Different pain treatments, includ-
ing local/topical options and systemic analgesics, are 
available and may be used for different intensities of infu-
sion site pain  [10] . In our cohort, mostly non-opioid an-
 Table 5. Summary of changes in clinical assessments from baseline 
Parameter Baseline Week 16 Change from
baseline
p value
Borg dyspnoea score (1 – 10)
Median
Q1
Q3
5.0
3.0
6.0
3.5
3.0
5.0
0.0
–1.0
0.5
0.1937
Patients, n 39 30a
WHO-FC, n (%)
II
III
IV
6 (15.4)
33 (84.6)
0 (0)
12 (30.8)
19 (48.7)
1 (3)
II–II: 4 (12.5)
II–III: 1 (3.1)
III–II: 8 (25.0)
III–III: 18 (56.3)
III–IV: 1 (3.1)
n.a.
Patients, n 39 32a 32
NT pro-BNP, pg/ml (n = 32)
Median
Q1
Q3
999
522
2,538
702
376
1,377
–182
–985
51
0.0081
Haemodynamics
PAPm, mm Hg (n = 29)a
Median
Q1
Q3
52.0
47
62
49.0
44
60
–4.0
–10
1
0.1115
Cardiac index, l/min/m2 (n = 29)a
Median
Q1
Q3
2.2
2
3
2.6
2
3
0.3
0
1
<0.0001
PVRI, mm Hg/min/m2/l (n = 29)a
Median
Q1
Q3
20.7
16
25
16.3
12
22
–2.7
–6
–1
<0.0001
SVRI, mm Hg/min/m2/l (n = 25)a
Median
Q1
Q3
36.1
31
42
29.7
25
36
–5.5
–8
–2
<0.0001
Echocardiography
TAPSE, cm
Median
Q1
Q3
1.6
1.4
1.9
1.8
1.6
2.0
0.1
0.0
0.3
0.0174
Patients, n 39 31a
TRJV, m/s
Median
Q1
Q3
Patients, n
4.40
4.00
4.74
38
3.90
3.40
4.53
27a
–0.3
–0.6
0.1
0.0068
WHO = World Health Organisation; NT pro-BNP = N-terminal pro-
brain natriuretic peptide; PAPm = mean pulmonary artery pressure;
PVRI = pulmonary vascular resistance index; SVRI = systemic vascular 
resistance index; TAPSE = tricuspid annular plane systolic excursion;
TRJV = tricuspid regurgitant jet velocity.
a Number of patients completing each assessment at week 16.
 Table 6. Treatment goals achieved at the end of the study (n = 39)
Subjects, n (%)
Treatment goal
Completed 16-week treatment period 32 (82)
WHO-FC II 12 (31)a
6MWD greater than 400 m 11 (28)b
TAPSE greater than 2 cm 6 (15)c
Number of treatment goals achieved
0 19 (49)
1 or more goals 20 (51)
1 12 (31)
2 7 (18)
3 1 (3)
a Four subjects were WHO-FC II at baseline and remained 
WHO-FC II at week 16, b Three subjects had a baseline walk 
greater than 400 m, all increased by more than 30 m at week 16,
c Two subjects had a TAPSE of greater than 2 cm at baseline and 
retained a value of greater than 2 cm at week 16.
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algesics were used. However, opioids were also prescribed 
on 35 occasions throughout the study, including mor-
phine in 5 cases. Up to now, little is known about the best 
point in time that pain treatment should begin. Whether 
a prophylactic pain management regimen that coincides 
with the start of the infusion may influence the intensity 
of infusion site pain and the overall tolerability of the 
treatment remains to be investigated. Other side effects 
included systemic adverse reactions typical of those as-
sociated with prostacyclin use, such as diarrhoea, head-
ache, nausea and vomiting.
 Our study results are consistent with previous reports 
of clinical improvements in 6MWD  [4, 5, 14] and haemo-
dynamics  [4] measured by RHC with a significant im-
provement of cardiac index and reduction of PVR. More 
than half of the patients in our cohort (51%) were consid-
ered to be treatment responders who achieved at least one 
of the pre-defined treatment goals at the end of the study 
period. Out of 20 patients showing a treatment response, 
18 improved until the end of the 16-week study period to 
reach at least one treatment goal, whilst 2 remained stable 
from baseline. It is important to recall that these subjects 
had severe PAH, with 85% in WHO-FC III at baseline. 
Furthermore, the majority of patients enrolled (90%) 
were established on dual oral background therapy, and 
the additional treatment response following 16 weeks of 
SC treprostinil indicates the effectiveness of a triple com-
bination intervention. As early treatment for PAH im-
proves long-term outcomes, the impact of such a triple 
therapy combination targeting the individual therapeutic 
targets of vascular pathology merits further investigation.
 The main limitations of our study are the small sample 
size and the study duration of 16 weeks. The patients of 
our study cohort were hospitalised for at least 72 h for the 
initial up-titration phase every 12 h. However, we assume 
that rapid, patient-triggered up-titration may also be fea-
sible in an ambulatory setting.
 As this study was intended to investigate the safety 
and tolerability of a rapid dose titration regimen, the 
main focus was on the titration phase. Thus, a long-term 
follow-up was not performed. As the titration phase oc-
curs principally during the first 3–4 months of treatment, 
the study allowed evaluation of safety and tolerability 
over the most crucial time period. Patients are more like-
ly to discontinue SC treprostinil during the initiation of 
therapy  [6] . All patients who completed the 16-week 
study period tolerated SC treprostinil well. Therefore, a 
significant deviation from discontinuation rates due to 
medication intolerance already reported in the literature 
is not expected.
 A further option to avoid SC infusion site pain and 
minimise the risk of blood stream infections associated 
with the presence of an in-dwelling central venous cath-
eter is to deliver IV treprostinil via an implanted infusion 
pump device, which has been successfully used both in 
neurology for intrathecal or epidural therapy and for the 
treatment of patients with PAH  [15–17] . The application, 
safety and tolerability of implantable pumps for IV trepro-
stinil therapy in PAH patients is currently being investi-
gated.
 Conclusion 
 Though many new agents have been developed for dis-
ease-specific therapy of PAH, prostanoids remain one of 
the most potent treatment options associated with im-
provement of exercise capacity, PAH symptoms and car-
diopulmonary haemodynamics. In this study, rapid dose 
titration led to earlier attainment of clinically effective 
dosages of SC treprostinil than is usually achieved during 
the titration phase, as described by the current European 
labelling for treprostinil  [18] . In combination with a pro-
active approach to infusion site pain management, an ac-
celerated titration scheme can be well tolerated, whilst 
more rapidly improving exercise capacity and haemody-
namics in patients with severe PAH already established 
on dual oral background therapy. A rapid dose titration 
regimen together with proactive infusion site pain man-
agement may therefore improve the management of this 
therapy and contribute to a better treatment outcome.
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